CRSR vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 29, 2026

CRSR

48.1
AI Score
VS
CRSR Wins

CLOV

39.1
AI Score

Investment Advisor Scores

CRSR

48score
Recommendation
HOLD

CLOV

39score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric CRSR CLOV Winner
Revenue 668.85M 1.49B CLOV
Net Income 21.63M 55.34M CLOV
Net Margin 3.2% 3.7% CLOV
Operating Income 21.40M 55.34M CLOV
ROE 3.3% 14.7% CLOV
ROA 1.8% 7.7% CLOV
Total Assets 1.22B 720.33M CRSR
Current Ratio 1.75 1.50 CRSR
Free Cash Flow 98.13M 131.55M CLOV

Relative Price Performance (Last 90 Days)

CRSR 1M: +19.2% · 3M: +55.6% CLOV 1M: -1.6% · 3M: -19.6%

Current Technical Phase

CRSR

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (14.5% over 20 days), RSI 64

RSI (14): 63.7 · Price: $13.85

CLOV

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.5%), weak momentum, RSI 41

RSI (14): 41.5 · Price: $4.23

Fundamentals Snapshot

Metric CRSR CLOV
Market Cap — —
Forward P/E 16.7 28.2
Trailing P/E 43.5 —
Revenue (TTM) — —
Revenue Growth 0.0% 0.6%
Gross Margin 0.3% 0.2%
Operating Margin 0.0% 0.0%
EPS 0.31 -0.05
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CRSR is currently the stronger investment candidate, winning 2 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.